Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | PIM1 | P11309 | 8/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.50 |
| ▸ | NAT1 | P18440 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185404 | 0.86 | HPGD (0.53) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6185401 | 0.86 | HPGD (0.53) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6204139 | 0.86 | GSK3B (0.52) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6204137 | 0.86 | GSK3B (0.52) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6184872 | 0.86 | PIM1 (0.55) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL5393236 | 0.82 | PIM1 (0.56) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL5393231 | 0.82 | PIM1 (0.56) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6186411 | 0.82 | GSK3B (0.52) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL6186415 | 0.82 | GSK3B (0.52) | GSK3BPIM1PIM2MEN1POLB | |
| SCHEMBL5397249 | 0.81 | MEN1 (0.53) | GSK3BPIM1PIM2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-7122564-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-17 | — | — | US | disclosed |
| EP-1458697-B1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RES & DEV (FR) | 2006-09-06 | — | — | EP | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1458697-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | Galderma Research & Development, S.N.C. (FR) | 2004-09-22 | — | — | EP | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | GSK3B 3034/4885PIM1 4639/4885PIM2 4701/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | GSK3B 3034/4885PIM1 4639/4885PIM2 4701/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | GSK3B 3283/4885PIM1 4577/4885PIM2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.